India’s MSN Laboratories Pvt. Ltd. has kicked off 2021 by launching four generics after receiving a raft of US Food and Drug Administration approvals during the first quarter. Through its US affiliate, Novadoz, the company has launched albendazole 200mg tablets; droxidopa 100mg, 200mg, 300mg capsules; deferasirox granules in 180mg and 360mg sachets; and pregabalin extended-release tablets in 82.5mg, 165mg and 330mg strengths.
Benefiting from the vertical integration of MSN’s manufacturing of active pharmaceutical ingredients, key starting materials and product intermediates, the company...